Cogstate Limited Share Price

Equities

CGS

AU000000CGS8

Biotechnology & Medical Research

Market Closed - Australian S.E. 09:51:14 17/05/2024 am IST 5-day change 1st Jan Change
1.29 AUD +3.20% Intraday chart for Cogstate Limited +0.78% -10.73%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 6.4Cr 4.29Cr 356.86Cr Sales 2025 * 7.86Cr 5.26Cr 437.78Cr Capitalization 22Cr 15Cr 1.23TCr
Net income 2024 * 50L 33.46L 28Cr Net income 2025 * 60L 40.15L 33Cr EV / Sales 2024 * 2.86 x
Net cash position 2024 * 3.7Cr 2.48Cr 206.11Cr Net cash position 2025 * 4.04Cr 2.7Cr 224.85Cr EV / Sales 2025 * 2.29 x
P/E ratio 2024 *
42.2 x
P/E ratio 2025 *
33.8 x
Employees 158
Yield 2024 *
-
Yield 2025 *
-
Free-Float 50.83%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.20%
1 week+0.78%
Current month-8.19%
1 month+3.61%
3 months+10.73%
6 months-11.64%
Current year-10.73%
More quotes
1 week
1.16
Extreme 1.155
1.30
1 month
1.16
Extreme 1.155
1.44
Current year
1.13
Extreme 1.125
1.48
1 year
1.13
Extreme 1.125
1.87
3 years
0.80
Extreme 0.8
2.68
5 years
0.16
Extreme 0.155
2.68
10 years
0.14
Extreme 0.14
2.68
More quotes
Managers TitleAgeSince
Founder - 17/99/17
Chief Executive Officer - 01/04/01
Director of Finance/CFO - 01/21/01
Members of the board TitleAgeSince
Chairman 65 -
Director/Board Member 57 26/10/26
Director/Board Member 50 29/19/29
More insiders
Date Price Change Volume
17/24/17 1.29 +3.20% 9,555
16/24/16 1.25 -3.10% 19,862
15/24/15 1.29 +3.20% 32,074
14/24/14 1.25 +1.21% 20,417
13/24/13 1.235 -3.52% 74,290

Delayed Quote Australian S.E., May 17, 2024 at 09:51 am IST

More quotes
Cogstate Limited is a neuroscience technology company optimizing brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Its principal activities are the creation, validation, and commercialization of digital brain health assessments; and design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments. Its segments include Clinical Trials, Healthcare, and Administration. In the Clinical Trials segment, the technology and associated services are used to quantify the effect of disease and of drugs, devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical, and biotechnology companies. In the Healthcare segment, the technology and associated services are being developed as a tool for primary care physicians and/or hospitals to assess cognitive decline.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.29 AUD
Average target price
1.8 AUD
Spread / Average Target
+39.53%
Consensus

Quarterly revenue - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW